Innoviva (INVA) versus Its Peers Critical Contrast
Innoviva (NASDAQ: INVA) is one of 104 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Innoviva to similar businesses based on the strength of its earnings, dividends, analyst recommendations, institutional ownership, risk, profitability and valuation.
Insider & Institutional Ownership
72.1% of Innoviva shares are held by institutional investors. Comparatively, 43.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.6% of Innoviva shares are held by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Innoviva and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Innoviva and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Innoviva||$133.57 million||$59.53 million||15.24|
|Innoviva Competitors||$8.17 billion||$1.09 billion||129.84|
Innoviva’s rivals have higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of recent ratings and recommmendations for Innoviva and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Innoviva presently has a consensus target price of $13.00, indicating a potential downside of 1.96%. As a group, “Pharmaceuticals” companies have a potential upside of 21.77%. Given Innoviva’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Innoviva has less favorable growth aspects than its rivals.
Risk & Volatility
Innoviva has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500. Comparatively, Innoviva’s rivals have a beta of 36.54, meaning that their average share price is 3,554% more volatile than the S&P 500.
Innoviva rivals beat Innoviva on 9 of the 13 factors compared.
Innoviva Company Profile
Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.
Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.